Ondine Biomedical Secures First NHS Commercial Deal with Antimicrobial Technology
TL;DR
Ondine Biomedical Inc sealed its first commercial deal with an NHS trust, gaining an early advantage in the healthcare market.
The success is attributed to Steriwave's effectiveness in reducing the need for antibiotics, leading to broader NHS adoption and deployment in healthcare facilities.
Ondine Biomedical's Steriwave is making the world a better place by improving healthcare outcomes, reducing antibiotic use, and contributing to antimicrobial resistance efforts.
Ondine Biomedical Inc is expanding its international presence in Canada, UK, and Spain, while also exploring potential in the United States through FDA phase three trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Ondine Biomedical Inc. has achieved a significant milestone with its first commercial agreement in the United Kingdom's National Health Service system. The Canadian antimicrobial photodisinfection specialist secured the deal with Pontefract and Pinderfields hospitals following a successful 500-patient elective hip and knee surgical quality initiative at Pontefract. This commercial adoption represents a crucial step in validating the company's Steriwave technology within the prestigious NHS framework.
Matt Ross, Vice President of Sales & Marketing at Ondine Biomedical, expressed enthusiasm about this development, noting that it follows demonstrated positive outcomes and favorable health economics. The company now plans to develop a comprehensive business case with the York health economics group and Mid Yorkshire to support broader NHS adoption across the United Kingdom. This strategic approach leverages the successful results from the initial implementation to build a compelling case for wider healthcare system integration.
The UK adoption forms part of Ondine's expanding commercial momentum globally. The technology is currently deployed in eight new healthcare facilities, bringing the total to 22 facilities across Canada while simultaneously expanding its presence in both the UK and Spain. This growth trajectory underscores the increasing recognition of Steriwave's potential in addressing critical healthcare challenges. The technology's effectiveness in reducing antibiotic requirements, as demonstrated in a UK study available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902345/, positions it as a valuable tool in antimicrobial resistance mitigation efforts.
Looking ahead, Ondine Biomedical intends to continue its European market expansion while capitalizing on established success in Canada. The company also plans to explore potential United States market entry through FDA phase three trials. This innovative antimicrobial photodisinfection approach represents a promising solution in the global fight against antibiotic resistance and healthcare-associated infections, offering an alternative methodology that could transform infection prevention protocols in surgical and clinical settings worldwide.
Curated from News Direct
